Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could clear psoriasis skin in 12 weeks

NCT ID NCT07489885

Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% improvement in psoriasis severity (PASI-90). The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
D-2570 tablet
What this could lead to
If successful, this could point toward a new oral treatment option for moderate to severe plaque psoriasis, potentially offering better skin clearance.
What could go wrong
This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent * Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3. * Within normal ranges of laboratory assessments Exclusion Criteria: * Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Study Center

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Study Center

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85008, United States

  • Study Center

    RECRUITING

    Chula Vista, California, 91910, United States

  • Study Center

    NOT_YET_RECRUITING

    Fountain Valley, California, 92708, United States

  • Study Center

    NOT_YET_RECRUITING

    Fremont, California, 94538, United States

  • Study Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90017, United States

  • Study Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90024, United States

  • Study Center

    NOT_YET_RECRUITING

    San Diego, California, 92123, United States

  • Study Center

    NOT_YET_RECRUITING

    Fort Lauderdale, Florida, 33308, United States

  • Study Center

    NOT_YET_RECRUITING

    Miramar, Florida, 33027, United States

  • Study Center

    NOT_YET_RECRUITING

    Ocala, Florida, 34470, United States

  • Study Center

    NOT_YET_RECRUITING

    Tampa, Florida, 33607, United States

  • Study Center

    NOT_YET_RECRUITING

    Sandy Springs, Georgia, 30328, United States

  • Study Center

    NOT_YET_RECRUITING

    Savannah, Georgia, 31419, United States

  • Study Center

    NOT_YET_RECRUITING

    Idaho Falls, Idaho, 83404, United States

  • Study Center

    NOT_YET_RECRUITING

    Clarksville, Indiana, 40241, United States

  • Study Center

    NOT_YET_RECRUITING

    Louisville, Kentucky, 40241, United States

  • Study Center

    NOT_YET_RECRUITING

    Mayfield Heights, Ohio, 44124, United States

  • Study Center

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

  • Study Center

    RECRUITING

    San Antonio, Texas, 78218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.